Craft

Advanced
  • Home
  •  / Precipio
Precipio

Precipio

Stock Price

$6.3

2024-10-29

Market Capitalization

$9.3 M

2024-10-29

Revenue

$18.5 M

FY, 2024

Precipio Summary

Company Summary

Overview
Precipio (formerly Transgenomic) is a company operating as a cancer diagnostics reference laboratory providing products and services to the oncology market. It develops a proprietary hematologic malignancy mutation profile screening panel and other products
Type
Public
Status
Active
Founded
1997
HQ
Omaha, NE, US | view all locations
Website
http://www.precipiodx.com/
Cybersecurity rating
Sectors

Table of Contents

Key People

  • Ilan Danieli

    Ilan Danieli, Chief Executive Officer, Director

  • Mark Rimer
  • Ron A. Andrews (Ronnie)

    Ron A. Andrews (Ronnie), Director

    • Richard Sandberg

      Richard Sandberg, Chairman of the Board

      LocationsView all

      4 locations detected

      • Omaha, NE HQ

        United States

        12325 Emmet St

      • New Haven, CT

        United States

        5 Science Park

      • Omaha, NE

        United States

        8813 F St

      • Glasgow, Scotland

        United Kingdom

        40 Watt Rd

      Precipio Financials

      Summary Financials

      Revenue (FY, 2024)
      $18.5M
      Gross profit (FY, 2024)
      $7.6M
      Net income (FY, 2024)
      ($4.3M)
      Cash (FY, 2024)
      $1.4M
      EBIT (FY, 2024)
      ($4.2M)
      Enterprise value
      $8.3M

      Competitors and Similar Companies

      Compare competitors

      Footer menu

      Product

      Solutions

      Resources

      Company

      © Craft.co 2025
      Share price data provided by IEX